Welcome to our dedicated page for HAVN LIFE SCIENCES news (Ticker: HAVLF), a resource for investors and traders seeking the latest updates and insights on HAVN LIFE SCIENCES stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HAVN LIFE SCIENCES's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HAVN LIFE SCIENCES's position in the market.
HAVN Life Sciences Inc. has signed a significant Supply Agreement with Allied Health, targeting the development of Psilonex™ RX Capsules containing psilocybin and natural health ingredients for individuals with PTSD. This marks the completion of HAVN's vision for a fully integrated supply chain from cultivation to encapsulation of psilocybin, a critical step in expanding its revenue opportunities. The agreement positions HAVN as a key supplier in a growing market for naturally derived psychedelic compounds.
HAVN Life Sciences Inc. has announced a partnership with Choices Markets to distribute its new line of natural health products. Launched on June 3, 2021, these products will be available across all Choices Markets locations later this month. CEO Tim Moore expressed excitement about the collaboration, emphasizing a commitment to health and wellness. The product line features seven formulations that are vegan, non-GMO, and designed to enhance brain health, supporting memory, focus, and cognitive function. The products will also be available online and through Amazon.
HAVN Life Sciences Inc. (CSE:HAVN, OTC PINK:HAVLF) announced the launch of seven new natural health products targeting brain health and immune function, available online and at select retailers starting June 3. The formulations include Mind Mushroom, Bacopa Brain, and others, utilizing high-quality mushroom and plant extracts designed to improve cognitive function and overall health. This launch is part of HAVN's strategy to establish a retail presence while continuing research on psychedelic compounds. The CEO highlighted this launch as a crucial milestone for brand development and market entry.
HAVN Life Sciences has completed its acquisition of clinical stage intellectual property from Bolt Therapeutics for $1 million, along with issuing 10,596,027 common shares. The acquired IP includes BOL-148, a compound showing potential in treating cluster headaches. The company aims to secure a patent and initiate preclinical studies to expedite drug development within four years. This strategic move positions HAVN Life to address a significant unmet medical need, as only one approved treatment exists for cluster headaches affecting 300,000 patients in the US.
HAVN Life Sciences Inc. (CSE:HAVN, OTC PINK:HAVLF) has announced a production and supply agreement with Lobe Sciences Ltd. The agreement allows HAVN Life to produce a range of Natural Health Products (NHP), focusing on plant-based compounds and non-psychoactive mushrooms. This strategic partnership aims to create an additional revenue stream and bolster HAVN Life's market presence. The company is set to launch its e-commerce platform and expand its distribution across Canada, following the recent acquisition of a manufacturing facility in Richmond, B.C.
HAVN Life Sciences Inc. (CSE:HAVN, OTC PINK:HAVLF) has entered a definitive agreement to acquire clinical stage intellectual property (IP) from Bolt Therapeutics, involving BOL-148, a compound showing promise for treating cluster headaches. With around 300,000 patients suffering from this condition in the U.S. and only one approved treatment available, HAVN Life sees a significant market opportunity. The acquisition involves a $1,000,000 payment and issuance of 15,894,040 shares, with plans to pursue Orphan Drug Designation and accelerated approvals.
Havn Life Sciences Inc. (CSE:HAVN, OTC PINK:HAVLF) will participate in the Q2 Virtual Investor Summit on May 17-18, 2021. CEO Tim Moore is set to present on May 17th at 11:45 ET, discussing the company's progress in psychoactive compound extraction and natural health products. The event will feature over 80 small cap companies and aims to connect them with qualified investors. Moore expressed enthusiasm about educating investors on market potential in the biotechnology space.
Havn Life Sciences Inc. (CSE:HAVN, OTC:HAVLF) has entered a supply agreement with ATMA Journey Centers, establishing Havn Life as the exclusive supplier of naturally-derived psilocybin in Alberta and Costa Rica. This partnership supports ATMA's growing demand for standardized psilocybin for psychedelic-assisted therapies for patients with end-of-life conditions, anxiety, and PTSD. Havn Life positions itself as a key supply chain provider, with CEO Tim Moore noting increased demand for therapeutic psychedelics and their operational facility in Jamaica now fully functional.
Havn Life Sciences has completed its analytical work under Health Canada’s Section 56 exemption. The company has developed a rapid testing method for measuring psilocybin content in under five minutes, aimed at enhancing the accuracy and quality of therapeutic compounds from Psilocybe spp. mushrooms. This achievement enables Havn Life to supply clinical trials with precise doses of psilocybin. The new testing methodology will support the operationalization of the company’s GMP compliant lab in Vancouver, driving advancements in psychedelic compound extraction and testing.
Havn Life Sciences has launched production at its new mycology lab in Jamaica, partnering with Hypha Wellness for psilocybin product development. The facility aims to produce naturally-derived psilocybin for clinical studies by Q4 2021, taking advantage of Jamaica's favorable legal environment for psychoactive mushrooms. Led by experienced experts, the operation seeks to foster partnerships within Jamaica's medicinal psilocybin industry, promoting sustainable practices and evidence-based research.
FAQ
What is the market cap of HAVN LIFE SCIENCES (HAVLF)?
